Clinical trial
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive…
NCT00048204 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00048204 |
|---|---|
| Title | A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder |
| Official title | An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients With Major Depressive Disorder |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Depressive Disorder, Major |
| Intervention type | Drug |
| Interventions | GW597599B, paroxetine |
| Enrollment | 372 |
| Start date | Nov 4, 2002 |
| Primary completion | Sep 30, 2003 |
| Completion | Sep 30, 2003 |
| First posted | Oct 30, 2002 |
| Last update posted | Oct 9, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: